{"name":"Avacta Life Sciences Ltd","slug":"avacta-life-sciences-ltd","ticker":"","exchange":"","domain":"","description":"Avacta Life Sciences Ltd is a biotechnology company focused on the development of novel cancer therapies and diagnostics. The company's pipeline includes two drugs, AVA6000 and AVA6103, both currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVA6000","genericName":"AVA6000","slug":"ava6000","indication":"Other","status":"phase_1"},{"name":"AVA6103","genericName":"AVA6103","slug":"ava6103","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AVA6000","genericName":"AVA6000","slug":"ava6000","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVA6103","genericName":"AVA6103","slug":"ava6103","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ0YxQmZYWGFOYUFFRmZHUHNzY3VoRFVockFhNktiNTVaQktLU0ZnUW4ydjNwXzJfQVQ0XzdUdEFKcG02bXhoc3NfZ0VBMkRHMDNEUUJkQk5IT3VMWXVhUUhTRU9sbDN0SVJDRWFpa1R1ZVZjQ3J4N0lmWWpzaUwxNnRHNExjQmFaWXNSdlAxRDlUUjQ?oc=5","date":"2026-04-08","type":"pipeline","source":"Share Talk","summary":"Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event - Share Talk","headline":"Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPc3Z6OXQ5S3FwOFpjNjExSkNuamg0M0p6ZFptbFBkS21HOEdPNlVsMGNfUWJubVFHNWhlaXl1RUVtTnY3UWNoOWthcFVlbmVoYkI1ckp2cEFYMXhKR3g3Z3dvcTAwQjlBV0Nla2VUS2hyRG9Rd1l1ZTluQ0Q1eUxCdnM0MVp3aXZrZUE2MVo3QkVNUEVOSGkzbDhzRktXTzdfR1EySUtVRXJMdEdI?oc=5","date":"2026-02-09","type":"pipeline","source":"Share Talk","summary":"Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer - Share Talk","headline":"Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM2VYZC1MRmE0Sl9RR21ka29RNGp1UEdwdW4xZ3FQeFVjXzdWc21DLXBBazl5MEpTb0dRMk1fR3ZIMGd3UkVmaVdhRGlSLW5wWmNUcFYweXJUeHYwOG1aOHo5dDdPRkcyUXdNNm5tY3FzWVJLZWRVd21HRU1NVWdiQUlMY0VlWmQ2RElEY1BhYzRTa19BTENidTFZa05CbEo0Nk1N?oc=5","date":"2026-01-21","type":"regulatory","source":"Share Talk","summary":"Avacta Therapeutics (AIM: AVCT) FDA Clearance of IND Application for AVA6103 - Share Talk","headline":"Avacta Therapeutics (AIM: AVCT) FDA Clearance of IND Application for AVA6103","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSjBsTW1lTkZRYkNiQVIyeXVKcVFMeVRpV0hWZ1hDNk0xMERUbVNObEpVWTBBOUg3MlhReGdBSHhKQUJ3SlVDWjNoc0s1RVpRRXhpeEZWVXdIZmtQMFVfTTFRVUdCOFVqOTA5NDBFcjdZNmV5MjlQYmNUVVA1Vnk4RVZWZ1p0Ti16Wm5hU19iNWdQaV9SNXFaS0xCUEx2UXFFbGJwTDhRUm53WHM?oc=5","date":"2025-12-08","type":"trial","source":"Share Talk","summary":"Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial - Share Talk","headline":"Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQVHBxMlk4Q3ZhWkpWWElQQWxGSFVLNlVoaFVmZzBsSDUwVjMzbmUyZVR0aENWLXFwcDR0RGdDblFtSDQzdEdxaHkzQ2pwSWxFT00xTGtNVzNIa3lybklGUmZGdGdCUEFGc2ZBRUFsTzBvM1ExbEVZbS05SUlmU05nYXBYazVIbTZGbkhaYjJKazJXajlYbVFzZFFvSXVtRnhIU1E?oc=5","date":"2025-12-07","type":"pipeline","source":"Share Talk","summary":"Welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub! - Share Talk","headline":"Welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOTU00dGZSc0tnTVRubm1ONFRIdTNPNWxqUllzSEJuMzhtcnB1M1BQdnN5THF3ak9kLUdTVkh4MEg3SFhxM29QOXhldjkxeVAydjU0UUY2Zmlybk4yTUlobUFHbTFzTU9nMThySHF6dzhOemhRaGtfOWRpMGhuZkpwa3llcjF1cUZfOVRhWFh2X1BkWkVEVV9uUWkybVVIZFk2S1FiTHF4QlF0Yk5OOFZF?oc=5","date":"2025-10-20","type":"pipeline","source":"thebusinessdesk.com","summary":"Life sciences firm raises £16m to fund oncology research - thebusinessdesk.com","headline":"Life sciences firm raises £16m to fund oncology research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPZWJueVpKWXNhWmtQTlJzRHlISGJZZGc0SndJR0lSRWUyNzRXT0FnclJwMTNtNkdncFJGazBLaGhfSE9vUHZJUkdDSFRZMG9CQ2w1YnJWOG5KTTFTc19KQWc1WWs0RTRPODY2TUZnSzdmLW5JSzlzVnZxMk9xeEtpVlIzaG5FNkZKTzZKTzN1TzRWVjY4amhmXzNYdENKR19wMk01UFU4NWdjS1VOMlpDZTcxVUJLSjYtV3pXb254RmlWVDctVnpJVk1IakpYb19aTWpIZnNScHhkZVM2SzRkRmt1YkdWTUJZWnloLTIta2VFTUZoNHJ5Ug?oc=5","date":"2025-08-13","type":"pipeline","source":"PR Newswire","summary":"GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight - PR Newswire","headline":"GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVXR3X1llcjZvcTktdnduWjhoZ1NRMUpCVGs4Qy14cXljSm92MUVTajNnX2g1S0ZwbjZJVFNaTWRtNTVMUG9lNW56cnZoMm54a190eklkak9hT2ZpWDVDeUJzRU91Z3otSXFEY1Nub0VrQ1BZZ2p5UmwzSGtxQldQb3p2Q1gwUmszSDFkdnJOYUdESUZPZ21aOHpqa3lVS05vVF81Wk01OE1XSUpqRmhjMDJId1JoVHFUS0ZNT05aWl85RVAzcnRNU1hXRTM2VWRqWlZtNE1BY1V6b2F5a2N3WGs2STFvNUxlalBv?oc=5","date":"2025-08-07","type":"pipeline","source":"PR Newswire UK","summary":"FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040 | DelveInsight - PR Newswire UK","headline":"FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOTlVSSDRESm1aRDlRc042TkwyOXh1eC1Oekl1THptcktDME9pTllDMkViOEg5RVFlclZndG9VMVBlcms2TV9iVVloNFF6YWRGbzFma0Q5UGQ4SFJtQlg1QTFoMjU3NFBrUzV0NUZBWGlQZ1pCSnZFaDNLVkJDTXBjMkg2SGRPY0ZpQ2xiQW04UFhjMFBOR2otcjRFVVdaMGVUX3dSbTBR?oc=5","date":"2025-03-10","type":"pipeline","source":"Share Talk","summary":"Avacta Group PLC (AIM:AVCT) Avacta to Present at Leerink Healthcare Conference - Share Talk","headline":"Avacta Group PLC (AIM:AVCT) Avacta to Present at Leerink Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxNYWZIR1FURDU4dFFXaEs3bjFkYk4zOERRa25WempmaDRMcndkNEtQTV81NTlUWWdONjNxLVdrNmlfMHBRZVU1a055NlhFLTVQcEs0LTNFWktRZDR1RHVtVjRIMzBuMVZuUFhDa01WT3lKaTY4ckZQRjFlSnc2YzNjTjhRbU5yYjN3NC1pSU1ZYTM3b1pVRjhyVVRxMGxRbFpmcUtoQ0VDTlY3VTJySExPM0t3a1JhU3pWUGROWV9yTmNHLXZ4UUZybzdDYS05R3lwRFozaGJHTkNFVjRTV0dfb2U5VDNEODhBaDdNTmJNNl9FUzJKT29ZV016Ynk0VTZjdjQ2S3NDV3paeVpWNDFUN2IzaFpKd0RZc21mSlZwTXhxeUVnNTRuQ0hQQ0pGamZTT1M5ZjNXZ1lGdU0zbzcteXdUWQ?oc=5","date":"2024-10-15","type":"trial","source":"globenewswire.com","summary":"Prostate Cancer Clinical Trial Pipeline Experiences - globenewswire.com","headline":"Prostate Cancer Clinical Trial Pipeline Experiences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWVpqb2Q1WjVBX09ONXlEOHVzTzlkSHlKdGEtSzcxc2hGYlM1T1E5SmdmaHA3TG8wQ1RWRF8tbmFiUGlJcm5rYVh6cUlQZWdDeGtFeGhhUHNOdkRvbXFIUGxLU2t4OEFFdDhyQ3lBa2hvaHJGZkNxV29XUkVZcmtTRA?oc=5","date":"2023-10-31","type":"pipeline","source":"Straits Research","summary":"Central Nervous System Biomarkers Market Size, Top Share, Forecast to 2033 - Straits Research","headline":"Central Nervous System Biomarkers Market Size, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOS01hMXJsTzVGLTB5eUtZNWh6ZVZMc2ZtanJWaWt0RG83RmVCWFV4b0lfbmRyeTRHN3lvSTRkaV9LRzFVWDVFZHdkX2lRdXA2RHlTR0FYUGtYbW40bDdNc3FCU1ZEMWladDBxVmd3WlpTcTYya0k0WGN0M216S1BIRnNMb2JZZ2FDOTBERVYwR0FaSzlvRnozN1FwcjJFVDJBa0o2SmZhMWppbkcyUHdoSjdER2RUS3FQNmtaQQ?oc=5","date":"2020-08-13","type":"pipeline","source":"News-Medical","summary":"Neil Bell appointed as Chief Development Officer of Avacta Life Sciences - News-Medical","headline":"Neil Bell appointed as Chief Development Officer of Avacta Life Sciences - News","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}